<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01129102</url>
  </required_header>
  <id_info>
    <org_study_id>NPC-01-2</org_study_id>
    <nct_id>NCT01129102</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of NPC-01 to Treat Dysmenorrhea</brief_title>
  <official_title>Phase 3, Placebo Controlled, Randomized, Double-blinded, Nonsteroidal Antiinflammatory Drug add-on, Clinical Trial of NPC-01 for Treatment of Dysmenorrhea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nobelpharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nobelpharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether NPC-01 is effective in the treatment of
      dysmenorrhea.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of this study is to confirm the effectiveness and safety profile of NPC-01
      in comparison with placebo in the treatment of dysmenorrhea (primary and secondary
      dysmenorrhea).

      Additionally we also investigate the differences of effectiveness of NPC-01 in comparison
      with IKH-01 in the treatment of secondary dysmenorrhea as a reference, because IKH-01 is
      already marketed at them.

      To achieve these, closed testing procedure is used in this study. After confirming
      statistical differences between NPC-01 and Placebo in the total dysmenorrhea, stratified
      analysis is carried out for primary dysmenorrhea (NPC-01, Placebo), and secondary
      dysmenorrhea (NPC-01, IKH-01 and Placebo).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient Response to Treatment for Dysmenorrhea, as Evaluated by Difference of Total Dysmenorrhea Score (Baseline/Pretreatment-End of Treatment)</measure>
    <time_frame>16weeks</time_frame>
    <description>The detail of dysmenorrhea score that was used in this study is the following. These subscales summed for a total dysmenorrhea score (minimum 0 to maximum 6). Pain score None 0 : None Mild 1 : There are some troubles for work Moderate 2 : Needing to rest in bed and/or affecting work Severe 3 : Morre than 1 day in bed and not possible to work
Drug score (during a menstrual period) None 0 : None Mild 1 : taking analgesics for 1 days Moderate 2 : taking analgesics for 2 days Severe 3 : taking analgesics more than 3 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in the VAS of Primary Dysmenorrhea (Baseline/Pretreatment-End of Treatment)</measure>
    <time_frame>16weeks</time_frame>
    <description>VAS stands for Visual Analogue Scale of pain. The scale was rated as a graphic rating scale. as a 100mm baseline from 0:No pain to 100:Worst possible pain.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">215</enrollment>
  <condition>Dysmenorrhea</condition>
  <arm_group>
    <arm_group_label>NPC-01</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Norethisterone 1mg, Ethinyl estradiol 0.02mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IKH-01</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Norethisterone 1mg, Ethinyl estradiol 0.035mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for NPC-01</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NPC-01</intervention_name>
    <description>Norethisterone 1mg, Ethinyl estradiol 0.02mg</description>
    <arm_group_label>NPC-01</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IKH-01</intervention_name>
    <description>Norethisterone 1mg, Ethinyl estradiol 0.035mg</description>
    <arm_group_label>IKH-01</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for NPC-01</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  dysmenorrhea

        Exclusion Criteria:

          -  severe hepatopathy

          -  pregnant woman
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naoki Terakawa, M.D.,Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Nissay Hospital,Osaka,Japan</affiliation>
  </overall_official>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2010</study_first_submitted>
  <study_first_submitted_qc>May 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2010</study_first_posted>
  <results_first_submitted>April 10, 2014</results_first_submitted>
  <results_first_submitted_qc>May 15, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 17, 2014</results_first_posted>
  <last_update_submitted>May 15, 2014</last_update_submitted>
  <last_update_submitted_qc>May 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dysmenorrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Norethindrone</mesh_term>
    <mesh_term>Norethindrone acetate</mesh_term>
    <mesh_term>Anti-Inflammatory Agents, Non-Steroidal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>NPC-01</title>
          <description>Norethisterone 1mg, Ethinyl estradiol 0.02mg
NPC-01: Norethisterone 1mg, Ethinyl estradiol 0.02mg</description>
        </group>
        <group group_id="P2">
          <title>IKH-01</title>
          <description>Norethisterone 1mg, Ethinyl estradiol 0.035mg
IKH-01: Norethisterone 1mg, Ethinyl estradiol 0.035mg</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo for NPC-01
Placebo: Placebo for NPC-01</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="110"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
                <participants group_id="P2" count="44"/>
                <participants group_id="P3" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>No study drug treatment</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline analysis population was carried out based on FAS data set. 110, 50 and 55 pts were assigned to NPC-01, IKH-01 and placebo, respectively, and administered study drug 108, 47 and 54 pts. Safety and FAS analysis was carried out on 107, 47 and 54 pts/105, 47 and 54 pts due to 1 and 2 pts of NPC-01 have no available data respectively.</population>
      <group_list>
        <group group_id="B1">
          <title>NPC-01</title>
          <description>Norethisterone 1mg, Ethinyl estradiol 0.02mg</description>
        </group>
        <group group_id="B2">
          <title>IKH-01</title>
          <description>Norethisterone 1mg, Ethinyl estradiol 0.035mg</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo for NPC-01</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="105"/>
            <count group_id="B2" value="47"/>
            <count group_id="B3" value="54"/>
            <count group_id="B4" value="206"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.4" spread="7.29"/>
                    <measurement group_id="B2" value="34.0" spread="6.93"/>
                    <measurement group_id="B3" value="30.4" spread="7.41"/>
                    <measurement group_id="B4" value="32.3" spread="7.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Under 30 years of age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 year of age and older</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="54"/>
                    <measurement group_id="B4" value="206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diagnostic categories</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Primary dysmenorrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Secondary dysmenorrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total dysmenorrhea score</title>
          <description>The detail of dysmenorrhea score that was used in this study is the following. These subscales summed for a total dysmenorrhea score (minimum 0 to maximum 6). Pain score None 0 : None Mild 1 : There are some troubles for work Moderate 2 : Needing to rest in bed and/or affecting work Severe 3 : Morre than 1 day in bed and not possible to work
Drug score (during a menstrual period) None 0 : None Mild 1 : taking analgesics for 1 days Moderate 2 : taking analgesics for 2 days Severe 3 : taking analgesics more than 3 days</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Total dysmenorrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.1" spread="1.00"/>
                    <measurement group_id="B2" value="NA">IKH-01 was not allocated for primary dysmenorrhea in this study. Therefore, total dysmenorrhea score is not available for IKH-01 group.</measurement>
                    <measurement group_id="B3" value="4.2" spread="0.95"/>
                    <measurement group_id="B4" value="NA">Data unavailable for IKH-01 group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Primary dysmenorrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.9" spread="0.92"/>
                    <measurement group_id="B2" value="NA">IKH-01 was not allocated for primary dysmenorrhea in this study.</measurement>
                    <measurement group_id="B3" value="4.3" spread="0.90"/>
                    <measurement group_id="B4" value="NA">Data unavailable for IKH-01 group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Secondary dysmenorrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.3" spread="1.05"/>
                    <measurement group_id="B2" value="4.0" spread="0.87"/>
                    <measurement group_id="B3" value="4.1" spread="0.99"/>
                    <measurement group_id="B4" value="4.1" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Visual analogue scale (VAS) for primary dysmenorrhea</title>
          <description>VAS stands for Visual Analogue Scale of pain. The scale was rated as a graphic rating scale. as a 100mm baseline from 0:No pain to 100:Worst possible pain.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.8" spread="20.57"/>
                    <measurement group_id="B2" value="NA">IKH-01 was not allocated for primary dysmenorrhea in this study. Therefore, VAS for primary dysmenorrhea is not available for IKH-01 group.</measurement>
                    <measurement group_id="B3" value="48.6" spread="20.15"/>
                    <measurement group_id="B4" value="NA">Data unavailable for IKH-01 group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Patient Response to Treatment for Dysmenorrhea, as Evaluated by Difference of Total Dysmenorrhea Score (Baseline/Pretreatment-End of Treatment)</title>
        <description>The detail of dysmenorrhea score that was used in this study is the following. These subscales summed for a total dysmenorrhea score (minimum 0 to maximum 6). Pain score None 0 : None Mild 1 : There are some troubles for work Moderate 2 : Needing to rest in bed and/or affecting work Severe 3 : Morre than 1 day in bed and not possible to work
Drug score (during a menstrual period) None 0 : None Mild 1 : taking analgesics for 1 days Moderate 2 : taking analgesics for 2 days Severe 3 : taking analgesics more than 3 days</description>
        <time_frame>16weeks</time_frame>
        <population>Primary endpoints were analysed based on FAS population. Data unavailable for IKH-01 group because IKH-01 group only assigned for secondary dysmenorrhea.</population>
        <group_list>
          <group group_id="O1">
            <title>NPC-01</title>
            <description>Norethisterone 1mg, Ethinyl estradiol 0.02mg
NPC-01: Norethisterone 1mg, Ethinyl estradiol 0.02mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for NPC-01
Placebo: Placebo for NPC-01</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Response to Treatment for Dysmenorrhea, as Evaluated by Difference of Total Dysmenorrhea Score (Baseline/Pretreatment-End of Treatment)</title>
          <description>The detail of dysmenorrhea score that was used in this study is the following. These subscales summed for a total dysmenorrhea score (minimum 0 to maximum 6). Pain score None 0 : None Mild 1 : There are some troubles for work Moderate 2 : Needing to rest in bed and/or affecting work Severe 3 : Morre than 1 day in bed and not possible to work
Drug score (during a menstrual period) None 0 : None Mild 1 : taking analgesics for 1 days Moderate 2 : taking analgesics for 2 days Severe 3 : taking analgesics more than 3 days</description>
          <population>Primary endpoints were analysed based on FAS population. Data unavailable for IKH-01 group because IKH-01 group only assigned for secondary dysmenorrhea.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pretreatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="1.00"/>
                    <measurement group_id="O2" value="4.2" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="1.57"/>
                    <measurement group_id="O2" value="2.9" spread="1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference in the VAS of Primary Dysmenorrhea (Baseline/Pretreatment-End of Treatment)</title>
        <description>VAS stands for Visual Analogue Scale of pain. The scale was rated as a graphic rating scale. as a 100mm baseline from 0:No pain to 100:Worst possible pain.</description>
        <time_frame>16weeks</time_frame>
        <population>This analysis was carried out based on FAS population. IKH-01 was not allocated for primary dysmenorrhea in this study. Therefore, VAS for primary dysmenorrhea is not available in IKH-01 group.</population>
        <group_list>
          <group group_id="O1">
            <title>NPC-01</title>
            <description>Norethisterone 1mg, Ethinyl estradiol 0.02mg
NPC-01: Norethisterone 1mg, Ethinyl estradiol 0.02mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for NPC-01
Placebo: Placebo for NPC-01</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in the VAS of Primary Dysmenorrhea (Baseline/Pretreatment-End of Treatment)</title>
          <description>VAS stands for Visual Analogue Scale of pain. The scale was rated as a graphic rating scale. as a 100mm baseline from 0:No pain to 100:Worst possible pain.</description>
          <population>This analysis was carried out based on FAS population. IKH-01 was not allocated for primary dysmenorrhea in this study. Therefore, VAS for primary dysmenorrhea is not available in IKH-01 group.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pretreatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.8" spread="20.57"/>
                    <measurement group_id="O2" value="48.6" spread="20.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.2" spread="20.18"/>
                    <measurement group_id="O2" value="35.6" spread="21.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From initiation of study drug to end of 6 cycle of menstrual, an average of 6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>NPC-01</title>
          <description>Norethisterone 1mg, Ethinyl estradiol 0.02mg
NPC-01: Norethisterone 1mg, Ethinyl estradiol 0.02mg</description>
        </group>
        <group group_id="E2">
          <title>IKH-01</title>
          <description>Norethisterone 1mg, Ethinyl estradiol 0.035mg
IKH-01: Norethisterone 1mg, Ethinyl estradiol 0.035mg</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo for NPC-01
Placebo: Placebo for NPC-01</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA-J 13.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain lower (Dysmenorrhoea aggravated)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA-J 13.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="103" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="107"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="19" subjects_affected="12" subjects_at_risk="107"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="107"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="17" subjects_affected="13" subjects_at_risk="107"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="47"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="107"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="71" subjects_affected="42" subjects_at_risk="107"/>
                <counts group_id="E2" events="16" subjects_affected="12" subjects_at_risk="47"/>
                <counts group_id="E3" events="31" subjects_affected="19" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Vulvovaginal candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="41" subjects_affected="25" subjects_at_risk="107"/>
                <counts group_id="E2" events="17" subjects_affected="10" subjects_at_risk="47"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Hypomenorrhoea</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="107"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="107"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" events="165" subjects_affected="75" subjects_at_risk="107"/>
                <counts group_id="E2" events="71" subjects_affected="37" subjects_at_risk="47"/>
                <counts group_id="E3" events="35" subjects_affected="21" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Oligomenorrhoea</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="38" subjects_affected="30" subjects_at_risk="107"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="47"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Polymenorrhoea</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="107"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Breast discomfort</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="107"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is an agreement between the sponsor and PI that no restricts the PI's right but need to discuss the timing of publish date of trial results after the trial is completed.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Department director of clinical development department 1</name_or_title>
      <organization>Nobelpharma</organization>
      <phone>+81-5651-1177</phone>
      <email>murakami@nobelpharma.co.jp</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

